Analyst consensus rating
Jade Biosciences Analyst Rating: none
JBIO is rated none by 8 analysts with a $50.13 target. As of 2026-08-27.
Direct answer
Jade Biosciences's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $50.13.
Forecast evidence checked August 27, 2026.
Get free Jade Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $21.29
- Average price target
- $50.13
- High price target
- $77.00
- Low price target
- $40.00
- Low target gap
- +87.9%
- Target upside
- +135.4%
- High target gap
- +261.7%
- Target range width
- 173.8%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Jade Biosciences?
Jade Biosciences has a verified none consensus. The same dataset has an average price target of $50.13.
How far are Jade Biosciences's low and high targets from the recorded price?
The low target implies +87.9%, while the high target implies +261.7%.
How many analysts are included in Jade Biosciences's consensus?
The verified consensus includes 8 analysts.
How is Jade Biosciences's target upside or downside calculated?
The average target of $50.13 is divided by the recorded price of $21.29, then one is subtracted to produce +135.4%. This does not guarantee a future return.
When was Jade Biosciences's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.